The global dry eye syndrome market size was valued at USD 7.81 billion in 2025 and is projected to grow from USD 8.35 billion in 2026 to USD 14.25 billion by 2034 at a CAGR of 6.92% during the forecast period 2026-2034. North America dominated the dry eye syndrome market with a market share of 38.6% in 2025.
Download a Free Sample To learn more about this report,
Dry eye syndrome (DES) is a multifactorial ocular condition characterised by tear film instability, leading to discomfort and visual disturbances. The increasing prevalence of DES is attributed to factors such as ageing populations, prolonged screen time, environmental pollution, and post-surgical complications. The global dry eye syndrome (DES) market is experiencing steady growth, driven by the increasing prevalence of digital device usage, environmental pollution, and an ageing population. Prolonged screen time reduces blink rates, leading to tear film instability and ocular discomfort. Environmental factors like air pollution and dry climates exacerbate these symptoms.
The Dry Eye Syndrome (DES) market is undergoing a wave of technological innovations to improve treatment efficacy and patient adherence. Notable advancements include the development of preservative-free formulations, enhanced drug delivery systems, and introduction devices that target the root causes of DES. Additionally, devices like TearCare and iLux, which use targeted thermal pulsation therapy, are transforming how meibomian gland dysfunction (MGD), a leading cause of evaporative dry eye, is treated. These devices provide non-invasive treatment options, offering convenience and improving patient compliance compared to traditional treatments like eye drops.
The Dry Eye Syndrome Market is witnessing increasing adoption of digital health technologies and artificial intelligence (AI) to improve the diagnosis, monitoring, and management of dry eye disease. AI-powered imaging systems, teleophthalmology platforms, and advanced ocular surface analysis tools are enabling eye care professionals to detect dry eye at earlier stages and develop personalized treatment plans. These technologies enhance diagnostic accuracy, reduce examination time, and improve patient outcomes by allowing continuous monitoring of disease progression. The growing integration of digital solutions into ophthalmology clinics and hospitals is also supporting better patient engagement and treatment adherence. As healthcare providers increasingly embrace smart diagnostic technologies, demand for AI-enabled dry eye management solutions is expected to rise, creating new growth opportunities for market participants.
The increasing prevalence of Dry Eye Syndrome (DES) has emerged as a key driver in the market's growth. According to the World Health Organisation, approximately 300 million people globally suffer from this condition, with the ageing population particularly at risk. Factors such as the widespread use of digital devices contribute to the rise of DES, which increases screen time and contributes to digital eye strain. This phenomenon, known as "computer vision syndrome," is becoming more common with the growing reliance on smartphones, computers, and tablets.
Additionally, increased awareness of the disease and its impact on quality of life has also spurred demand for more targeted treatments, further expanding the market. Companies like Allergan and Johnson & Johnson have responded to this surge by introducing new over-the-counter products to alleviate the discomfort associated with DES, and the growing focus on holistic eye health is expected to drive market growth in the coming years.
Despite the availability of various treatments, the high cost of advanced therapies remains a significant restraint on the growth of the Dry Eye Syndrome (DES) market. Prescription medications, such as Restasis (cyclosporine A) and Xiidra (lifitegrast), which aim to reduce eye inflammation, can be expensive, with monthly treatment costs sometimes exceeding $500. Additionally, the growing popularity of innovative devices like the LipiFlow Thermal Pulsation System, which costs over $2,000 per treatment session, presents affordability challenges for many patients. These high treatment costs can make advanced DES therapies inaccessible, especially in regions with lower healthcare spending or inadequate insurance coverage.
Moreover, while devices like iLux and TearCare offer targeted relief, they require multiple sessions, contributing to a growing financial burden for patients who need regular treatments. This challenge is particularly pronounced in low- and middle-income countries, where the cost of healthcare and limited insurance options restrict access to these advanced solutions. With healthcare providers prioritising more cost-effective, accessible treatments, the high price point of cutting-edge therapies represents a significant barrier to widespread adoption, limiting the market's growth potential.
The Dry Eye Syndrome Market presents significant opportunities through the development of personalized treatment approaches and regenerative therapies. Advances in biologics, autologous serum eye drops, stem cell-based therapies, and AI-assisted diagnostics are enabling more targeted and effective treatment for patients with moderate to severe dry eye disease. Additionally, the growing adoption of teleophthalmology and digital eye health platforms is improving early diagnosis and treatment accessibility.
One of the major challenges in the Dry Eye Syndrome Market is the delayed diagnosis of the condition due to its nonspecific symptoms, which are often mistaken for general eye irritation or fatigue. The absence of universally accepted diagnostic protocols and variations in disease severity make treatment selection more complex for healthcare professionals. Additionally, patient adherence to long-term therapy remains low, as many treatments require continuous use before noticeable improvement is achieved. These factors can delay effective disease management and limit the adoption of advanced dry eye therapies.
Request Customizationto receive a tailored report.
The Artificial Tears segment dominated the Dry Eye Syndrome Market, accounting for 31.80% of the global market share in 2025. The segment's leadership is attributed to the widespread use of artificial tears as the first-line treatment for mild to moderate dry eye symptoms. These products provide immediate lubrication, relieve ocular discomfort, and are available in various formulations, including preservative-free and long-lasting variants. Their over-the-counter availability, affordability, and ease of use have contributed to their high adoption among patients. Furthermore, the increasing prevalence of digital eye strain, aging populations, and rising awareness of eye health continue to drive demand for artificial tears worldwide.
The Online Pharmacies segment is expected to witness the fastest growth, registering a CAGR of 7.14% during the forecast period (2026–2034). The segment's growth is driven by increasing internet penetration, expanding e-commerce platforms, and the growing preference for convenient home delivery of healthcare products. Online pharmacies offer a wide range of prescription and over-the-counter dry eye treatments, competitive pricing, and easy access for patients in remote areas. Additionally, the rapid adoption of telemedicine and digital healthcare services has encouraged online prescription fulfillment, while attractive discounts, subscription services, and doorstep delivery continue to boost consumer preference for purchasing dry eye products through online channels.
Speak to an Analystto discuss market opportunities.
The U.S. accounted for approximately USD 2.56 billion of the regional market in 2025, driven by the high prevalence of dry eye disease, increasing screen time, advanced healthcare infrastructure, and widespread adoption of prescription therapies and innovative ophthalmic devices.
Canada contributed approximately USD 0.45 billion in 2025, supported by increasing awareness of ocular health, improved access to ophthalmology services, and growing demand for preservative-free artificial tears and digital eye care solutions.
Germany represented approximately USD 0.71 billion of the European market in 2025, owing to its advanced ophthalmology infrastructure, strong reimbursement policies, and early adoption of innovative dry eye treatments.
The UK contributed approximately USD 0.49 billion in 2025, driven by increasing digital device usage, rising awareness of dry eye syndrome, and expanding availability of prescription and over-the-counter therapies.
Japan generated approximately USD 0.54 billion in 2025, supported by its ageing population, high incidence of meibomian gland dysfunction, and widespread use of advanced ophthalmic treatments.
China accounted for approximately USD 0.63 billion in 2025, driven by rapid healthcare infrastructure development, increasing disposable income, expanding eye care services, and growing awareness of dry eye syndrome.
Brazil represented approximately USD 0.19 billion in 2025, benefiting from its large patient population, expanding ophthalmology clinics, improving healthcare infrastructure, and increasing availability of dry eye therapies.
The UAE contributed approximately USD 0.07 billion in 2025, supported by advanced healthcare facilities, growing medical tourism, increasing adoption of premium ophthalmic treatments, and government initiatives aimed at strengthening eye care services.
Unlock Regional Insightsto access country-level data, & regional trends.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a Healthcare Lead with over 7 years of industry experience, specializing in Healthcare IT. She provides comprehensive market insights on digital health, electronic medical records, telehealth, and healthcare analytics. Debashree’s research supports organizations in adopting technology-driven healthcare solutions, improving patient care, and achieving operational efficiency in a rapidly transforming healthcare ecosystem.
We are featured on:
sales@straitsresearch.com